Correction: Correlations between integrin ανβ6 expression and clinico-pathological features in stage B and stage C rectal cancer (PLoS ONE (2014) 9, 5 (e97248) DOI: 10.1371/journal.pone.0097248);Correlations between integrin ανβ6 expression and clinico-pathological features in stage B and stage C rectal cancer

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Ahn, Seong Beom ^a,b   Mohamedali, Abidali ^a,b   Chan, Charles ^c   Fletcher, Julie ^c   Kwun, Sun Young ^c   Clarke, Candice ^c   Dent, Owen F ^c   Chapuis, Pierre H ^c   Nice, Edouard ^d   Baker, Mark S ^a,b  

^a MACQUARIE UNIVERSITY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA6 INTEGRIN; INTEGRIN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RECTUM CANCER; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR GROWTH; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; RECTUM TUMOR; SURVIVAL; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECTAL NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84901247443     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104724     Document Type: Erratum

References (36)

1. Davis NC, Newland RC (1983) Terminology and classification of colorectal adenocarcinoma: the Australian clinico-pathological staging system. Aust N Z J Surg 53: 211-221.
2. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-856.
3. Bandyopadhyay A, Raghavan S (2009) Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets 10: 645-652.
4. Patsenker E, Wilkens L, Banz V, Osterreicher CH, Weimann R, et al. (2010) The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma. J Hepatol 52: 362-369.
5. Liu S, Liang B, Gao H, Zhang F, Wang B, et al. (2013) Integrin alphavbeta6 as a novel marker for diagnosis and metastatic potential of thyroid carcinoma. Head Neck Oncol 5: 7.
6. Zhuang Z, Zhou R, Xu X, Tian T, Liu Y, et al. (2013) Clinical significance of integrin alphavbeta6 expression effects on gastric carcinoma invasiveness and progression via cancer-associated fibroblasts. Med Oncol 30: 013-0580.
7. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687.
8. Ahmed N, Riley C, Rice GE, Quinn MA, Baker MS (2002) Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J Histochem Cytochem 50: 1371-1380.
9. Jones J, Watt FM, Speight PM (1997) Changes in the expression of alpha v integrins in oral squamous cell carcinomas. J Oral Pathol Med 26: 63-68.
10. Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, et al. (2004) Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong upregulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 45: 226-236.
11. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, et al. (2005) Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 115: 339-347.
12. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
13. Xu J, Lamouille S, Derynck R (2009) TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172.
14. Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, et al. (2008) Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res 68: 561-570.
15. Ahmed N, Niu J, Dorahy DJ, Gu X, Andrews S, et al. (2002) Direct integrin alphavbeta6-ERK binding: implications for tumour growth. Oncogene 21: 1370-1380.
16. Gu X, Niu J, Dorahy DJ, Scott R, Agrez MV (2002) Integrin alpha(v)beta6-associated ERK2 mediates MMP-9 secretion in colon cancer cells. Br J Cancer 87: 348-351.
17. Morgan MR, Thomas GJ, Russell A, Hart IR, Marshall JF (2004) The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. J Biol Chem 279: 26533-26539.
18. Bokey EL, Ojerskog B, Chapuis PH, Dent OF, Newland RC, et al. (1999) Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: role of total anatomical dissection. Br J Surg 86: 1164-1170.
19. Newland RC, Chapuis PH, Pheils MT, MacPherson JG (1981) The relationship of survival to staging and grading of colorectal carcinoma: a prospective study of 503 cases. Cancer 47: 1424-1429.
20. Newland RC, Chapuis PH, Smyth EJ (1987) The prognostic value of substaging colorectal carcinoma. A prospective study of 1117 cases with standardized pathology. Cancer 60: 852-857.
21. Darakhshan A, Lin BP, Chan C, Chapuis PH, Dent OF, et al. (2008) Correlates and outcomes of tumor adherence in resected colonic and rectal cancers. Ann Surg 247: 650-658.
22. Keshava A, Chapuis PH, Chan C, Lin BP, Bokey EL, et al. (2007) The significance of involvement of a free serosal surface for recurrence and survival following resection of clinicopathological stage B and C rectal cancer. Colorectal Dis 9: 609-618.
23. Fielding LP, Arsenault PA, Chapuis PH, Dent O, Gathright B, et al. (1991) Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol 6: 325-344.
24. Hecht JL, Dolinski BM, Gardner HA, Violette SM, Weinreb PH (2008) Overexpression of the alphavbeta6 integrin in endometrial cancer. Appl Immunohistochem Mol Morphol 16: 543-547.
25. Weinreb PH, Simon KJ, Rayhorn P, Yang WJ, Leone DR, et al. (2004) Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligandmimetic and nonligand-mimetic classes. J Biol Chem 279: 17875-17887.
26. Zhang ZY, Xu KS, Wang JS, Yang GY, Wang W, et al. (2008) Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma. Clin Oncol 20: 61-66.
27. Kho PS, Jankova L, Fung CL, Chan C, Clarke C, et al. (2012) Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front. Int J Colorectal Dis 27: 1409-1417.
28. Hazelbag S, Kenter GG, Gorter A, Dreef EJ, Koopman LA, et al. (2007) Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol 212: 316-324.
29. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: A Cancer Journal for Clinicians 61: 69-90.
30. Pepper MS (2001) Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21: 1104-1117.
31. Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290.
32. Smith HW, Marshall CJ (2010) Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11: 23-36.
33. Mekkawy AH, Morris DL, Pourgholami MH (2009) Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol 5: 1487-1499.
34. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, et al. (1995) Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 108: 2241-2251.
35. Saha A, Ellison D, Thomas GJ, Vallath S, Mather SJ, et al. (2010) High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6. J Pathol 222: 52-63.
36. Trujillo KA, Heaphy CM, Mai M, Vargas KM, Jones AC, et al. (2011) Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 129: 1310-1321.